Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2023-01-18 Major Shareholding Noti…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Zawiadomienie o zmianie stanu posiadania akcji Spółki - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document text is very short (713 characters) and explicitly states that the Management Board ('Zarząd') received a notification ('zawiadomienie') regarding a change in share ownership ('zmianie stanu posiadania akcji') from TFI Allianz Polska S.A. and is transmitting the content of this notification attached to the current current report ('niniejszym raportu bieżącego'). This structure—announcing the receipt of information and attaching the details—strongly suggests a regulatory notification filing. The reference to 'art. 70 pkt 1 ustawy z dnia 29 lipca 2005 r. o ofercie publicznej' (Polish Public Offering Act) confirms it is a mandatory regulatory disclosure. Since the content is a notification about a change in major shareholding (crossing thresholds), the most specific category is Major Shareholding Notification (MRQ). If MRQ were not available, RNS would be the fallback, but MRQ is a better fit for changes in ownership percentage.
2023-01-18 Polish
Tekst jednolity Statutu Spółki Pure Biologics S.A. uwzględniający zmiany
Regulatory Filings Classification · 98% confidence The document text provided is a consolidated version of the Articles of Association (Statut Spółki Akcyjnej) for Pure Biologics S.A., written in Polish. It details the company's name, seat, business scope (PKD codes), capital structure (including share types, nominal value, and conditional increases), and rules regarding share transfer and pre-emptive rights. This type of foundational corporate governance document, which outlines the structure and rules of the company, is best classified as Governance Information (CGR). It is not an Annual Report (10-K), an Earnings Release (ER), or a specific regulatory filing like a Director's Dealing (DIRS) or a Dividend Notice (DIV). Since the content is the core governing document, CGR is the most appropriate fit.
2023-01-13 Polish
Treść zmienionych postanowień Statutu Spółki Pure Biologics S.A.
Share Issue/Capital Change Classification · 98% confidence The document text, written in Polish, details amendments to the company's Articles of Association (Statut Spółki) resulting from a resolution to increase the share capital (podwyższenia kapitału zakładowego) through the issuance of new shares (emisji nowych akcji serii G i H) via private subscription, and the subsequent declaration of the new total share capital amount. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document is not a short announcement of a report, but the substantive filing detailing the capital change itself.
2023-01-13 Polish
Rejestracja podwyższenia kapitału zakładowego Spółki w wyniku emisji akcji serii G i H oraz rejestracja zmian Statutu Spółki - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document text, written in Polish, announces the registration of changes to the Company's Articles of Association (Statut Spółki) following a capital increase through the issuance of new shares (series G and H). It details the new total share capital (321,400 PLN) and the breakdown of all existing share series. The final paragraph explicitly states that the text of the amended Articles of Association and the consolidated text incorporating the changes are attached to the report ("w załączeniu do niniejszego raportu, przedstawia treść zmienionych postanowień Statutu Spółki oraz tekst jednolity Statutu uwzględniający zmiany"). Since this is an announcement regarding the registration of capital changes and the attachment of related statutory documents, it strongly aligns with the 'Capital/Financing Update' (CAP) category, which covers capital structure changes. Although it mentions attaching documents, the core subject is the capital change registration itself, making CAP more specific than a general RPA or RNS.
2023-01-13 Polish
Zawarcie umowy dotyczącej pierwszego podania u ludzi kandydatów na leki w projektach PB003 i PB004 - tzw. badania klinicznego fazy 0 - Content (PL)
Regulatory Filings Classification · 97% confidence The document text is a formal announcement by the management board ('Zarząd') of Pure Biologics S.A. regarding the execution of an agreement with Presage Biosciences Inc. for conducting Phase 0 clinical trials for drug candidates PB003 and PB004. This announcement details a significant business transaction, specifically related to drug development and clinical testing, which impacts the company's operations and future commercialization prospects. This type of material, detailing strategic business agreements and development milestones, is often classified as a general regulatory announcement or a material event disclosure. Since there is no specific category for 'Material Business Agreement' or 'Clinical Trial Update,' and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or director dealing (DIRS), the most appropriate general category for significant, non-standard regulatory disclosures is 'Regulatory Filings' (RNS). The document length (2223 chars) is short enough that it could potentially be an announcement of a larger event, but the content itself is the core disclosure of the agreement, making RNS the best fit among the provided options.
2022-12-27 Polish
Zawiadomienie na podstawie art. 69 Ustawy o Ofercie_PKO BP BANKOWY PTE
Major Shareholding Notification Classification · 99% confidence The document is titled "ZAWIADOMIENIE DOTYCZĄCE STANU POSIADANIA AKCJI SPÓŁKI PUBLICZNEJ" (Notification regarding the holding of shares in a public company). It details changes in share ownership percentages (crossing the 5% threshold) by PKO BP Bankowy Otwarty Fundusz Emerytalny and PKO Dobrowolny Fundusz Emerytalny in PURE BIOLOGICS S.A., referencing specific articles of Polish public offering law (Ustawa o Ofercie). This type of filing, which reports changes in significant shareholdings, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal notification, not a general regulatory filing (RNS) or a report itself.
2022-12-22 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.